Loading…
Allergy Testing Access Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Allergy Testing Access Act of 2019 This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare. Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2021 · first_quarter · Health Issues
- H.R. 2009, Removing Barriers to Allergy Diagnostic Testing; S. 2246 Allergy Testing Access Act of 2019 - equal coverage of initiative specific immunoglobulin tests and percutaneous tests for allergies under Medicaid and Medicare Programs - H.R. 6102 - Verifying Accurate Leading-Edge IVCT Development Act - modernize regulation of -clinical laboratory tests - COVID-19 testing in congregate settings, schools, businesses. - Utility of serology testing and vaccine rollouts - Regulate independent device service businesses - Medicare reimbursement for diagnostic radiopharmaceuticals in the Hospital Outpatient Department - Regulation and coverage and payment for imaging artificial intelligence - Medical device user fees
Client expense: $450,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2021 · first_quarter · Health Issues
- H.R. 2009, Removing Barriers to Allergy Diagnostic Testing; S. 2246 Allergy Testing Access Act of 2019 - equal coverage of initiative specific immunoglobulin tests and percutaneous tests for allergies under Medicaid and Medicare Programs - H.R. 6102 - Verifying Accurate Leading-Edge IVCT Development Act - modernize regulation of -clinical laboratory tests - COVID-19 testing in congregate settings, schools, businesses. - Utility of serology testing and vaccine rollouts - Regulate independent device service businesses - Medicare reimbursement for diagnostic radiopharmaceuticals in the Hospital Outpatient Department - Regulation and coverage and payment for imaging artificial intelligence - Medical device user fees
Client expense: $450,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $950,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Medicare/Medicaid
Monitor implementation of H.R. 1865, Further Consolidated Appropriations Act, 2020, (Public Law 116-94) and provisions related to policies regarding data collection from laboratories under the Protecting Access to Medicare Act (PAMA) S. 2246, Allergy Testing Access Act of 2019, and H.R. 2009, the Removing Barriers to Allergy Diagnostic Tests Act, and provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests H.R. 1765, the Donald Payne Sr. Colorectal Cancer Detection Act H.R. 8702/S. 5007, the Holding Providers Harmless from Medicare Cuts During COVID-19 Act
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
2020 · fourth_quarter · Health Issues
H.R. 2009, S2246 - Removing Barriers to Allergy Diagnostic Testing Act
Client expense: Not reported · Firm income: $30,000
Government targets: SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement and policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 preparedness products and services PASTEUR Act (S.4760)
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019; COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $1,060,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2020 · third_quarter · Medicare/Medicaid
Monitor implementation of H.R. 1865, Further Consolidated Appropriations Act, 2020, (Public Law 116-94) and provisions related to policies regarding data collection from laboratories under the Protecting Access to Medicare Act (PAMA). S. 2246, Allergy Testing Access Act of 2019, and H.R. 2009, the Removing Barriers to Allergy Diagnostic Tests Act, and provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests.
Client expense: $220,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement PASTEUR Act (S.4760)
Client expense: $370,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Budget/Appropriations
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Medicare/Medicaid
Monitor implementation of H.R. 1865, Further Consolidated Appropriations Act, 2020, (Public Law 116-94) and provisions related to policies regarding data collection from laboratories under the Protecting Access to Medicare Act (PAMA). S. 2246, Allergy Testing Access Act of 2019, and H.R. 2009, the Removing Barriers to Allergy Diagnostic Tests Act, and provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests.
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 and COVID-4 omnibus package; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019 and S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2020 · second_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Budget/Appropriations
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Medicare/Medicaid
H.R. 3772, Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 legislation to provide separate payments for PET DRUGS in the hospital outpatient settings; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019 and S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $990,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2020 · first_quarter · Budget/Appropriations
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID preparedness products and services (H.R. 748)
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · first_quarter · Budget/Appropriations
H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019; Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
2020 · first_quarter · Health Issues
H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019; Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
2020 · first_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 6201, the Families First Coronavirus Response Act, provisions relating to coverage of and funding for COVID-19 diagnostic tests; H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, funding for child care for laboratory personnel, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed; S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests; Federal policy relating to drug development; Federal policy relating to implementation of anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential inclusion in the Fiscal Year 2021 Labor-HHS appropriations bill; and Federal policy relating to FDA oversight of pharmacogenetic tests, including potential inclusion in the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Client expense: $590,000 · Firm income: Not reported
2019 · fourth_quarter · Medicare/Medicaid
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
2019 · fourth_quarter · Medicare/Medicaid
Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019
Client expense: Not reported · Firm income: Not reported
2019 · fourth_quarter · Medicare/Medicaid
H.R.3584, Laboratory Access for Beneficiaries Act - Medicare Reimbursement of clinical laboratory tests and Draft legislation to provide separate payment for PET drugs in the hospital outpatient setting; H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019 and S.2246, Allergy Testing Access Act of 2019 - equal coverage of initiative-specific Immunoglobulin (IgE) tests and percutaneous test for allergies under Medicaid and Medicare Programs.
Client expense: $870,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Health Issues
S. 2246- diagnostic testing; H.R. 1865 - consolidated appropriations
Client expense: Not reported · Firm income: $30,000
Government targets: SENATE
2019 · fourth_quarter · Health Issues
Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393)
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE
2019 · fourth_quarter · Medicare/Medicaid
H.R.2009, Removing Barriers to Allergy Diagnostic Testing Act of 2019; S.2246, Allergy Testing Access Act of 2019; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Client expense: Not reported · Firm income: $40,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies. H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act; H.R. 3235, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counseling services, and S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare and Medicaid coverage of allergy diagnostic tests; Cures 2.0, potential legislative initiative (Reps. Upton and DeGette); Federal policy relating to drug development; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); Federal policy relating to subject matter eligibility for patents of laboratory tests; and H.R. 3630, the No Surprises Act, H.R. 2328, the Reauthorizing and Extending Americas Community Health (REACH) Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
Client expense: $280,000 · Firm income: Not reported
2019 · third_quarter · Health Issues
Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393)
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office
2019 · third_quarter · Health Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act, H.R. 3235, the Access to Genetic Counselor Services Act, and S. 2246, the Removing Barriers to Allergy Diagnostic Tests Act, provisions relating to Medicare, Medicaid and TRICARE coverage and reimbursement for laboratory services and reforms to the Clinical Laboratory Fee Schedule; Federal policy relating to drug development; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); Federal policy relating to subject matter eligibility for patents of laboratory tests; and H.R. 3630, the No Surprises Act, H.R. 2328, the Reauthorizing and Extending Americas Community Health (REACH) Act, and S. 1895, the Lower Health Care Costs Act, provisions relating to surprise medical billing.
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| WV |
| Sherrod Brown | Democratic | OH |
| Tim Scott | Republican | SC |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE